Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paola Malaguti

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Expert Opinion on Pharmacotherapy|February 19, 2013
An update on palonosetron hydrochloride for the treatment of radio/chemotherapy-induced nausea and vomitingAlessandra Fabi, Paola Malaguti
The Lancet. Oncology|March 8, 2016
Palbociclib: efficacious but predictive biomarkers still neededFrancesco Cognetti, Paola Malaguti, Daniele Alesini
Anticancer Research|December 26, 2012
The Mammalian target of rapamycin inhibitors in breast cancer: current evidence and future directionsPaola Malaguti, Sabrina Vari, Francesco Cognetti, et al.
Journal of Experimental & Clinical Cancer Research : CR|July 1, 2016
First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?Alessandra Fabi, Paola Malaguti, Sabrina Vari, et al.
Gynecologic Oncology Case Reports|December 28, 2013
Unusual liver locations of growing teratoma syndrome in ovarian malignant germ cell tumorsDomenica Lorusso, Paola Malaguti, Ilaria Nausica Trivellizzi, et al.
Oncology|July 25, 2018
Activity of Eribulin Mesylate in Brain Metastasis from Breast Cancer: A Stone in a Pond?Giovanna Catania, Paola Malaguti, Simona Gasparro, et al.
Recenti Progressi in Medicina|September 17, 2010
[Pharmacogenomics and chemotherapy]Ida Paris, Gian Carlo Antonini Cappellini, Paola Malaguti, et al.
International Journal of Molecular Sciences|November 13, 2020
AXL Receptor in Breast Cancer: Molecular Involvement and Therapeutic LimitationsItalia Falcone, Fabiana Conciatori, Chiara Bazzichetto, et al.
BMC Cancer|December 16, 2014
Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter studyGabriella Ferrandina, Giacomo Corrado, Floriana Mascilini, et al.
Cancer|June 29, 2004
Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinomaMichele Milella, Alain Gelibter, Serena Di Cosimo, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Expert Opinion on Pharmacotherapy|February 19, 2013
An update on palonosetron hydrochloride for the treatment of radio/chemotherapy-induced nausea and vomitingAlessandra Fabi, Paola Malaguti
The Lancet. Oncology|March 8, 2016
Palbociclib: efficacious but predictive biomarkers still neededFrancesco Cognetti, Paola Malaguti, Daniele Alesini
Anticancer Research|December 26, 2012
The Mammalian target of rapamycin inhibitors in breast cancer: current evidence and future directionsPaola Malaguti, Sabrina Vari, Francesco Cognetti, et al.
Journal of Experimental & Clinical Cancer Research : CR|July 1, 2016
First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?Alessandra Fabi, Paola Malaguti, Sabrina Vari, et al.
Gynecologic Oncology Case Reports|December 28, 2013
Unusual liver locations of growing teratoma syndrome in ovarian malignant germ cell tumorsDomenica Lorusso, Paola Malaguti, Ilaria Nausica Trivellizzi, et al.
Oncology|July 25, 2018
Activity of Eribulin Mesylate in Brain Metastasis from Breast Cancer: A Stone in a Pond?Giovanna Catania, Paola Malaguti, Simona Gasparro, et al.
Recenti Progressi in Medicina|September 17, 2010
[Pharmacogenomics and chemotherapy]Ida Paris, Gian Carlo Antonini Cappellini, Paola Malaguti, et al.
International Journal of Molecular Sciences|November 13, 2020
AXL Receptor in Breast Cancer: Molecular Involvement and Therapeutic LimitationsItalia Falcone, Fabiana Conciatori, Chiara Bazzichetto, et al.
BMC Cancer|December 16, 2014
Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter studyGabriella Ferrandina, Giacomo Corrado, Floriana Mascilini, et al.
Cancer|June 29, 2004
Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinomaMichele Milella, Alain Gelibter, Serena Di Cosimo, et al.
Pageof 2